Search Within
V900323
Applied Filters:
Keyword:'V900323'
Showing 1-30 of 210 results for "V900323" within Papers
Siana Nkya Mtatiro et al.
American journal of hematology, 90(1), E1-E4 (2014-09-30)
Fetal hemoglobin (HbF) is a recognized modulator of sickle cell disease (SCD) severity. HbF levels are strongly influenced by genetic variants at three major genetic loci, Xmn1-HBG2, HMIP-2, and BCL11A, but the effect of these loci on the hematological phenotype
Choon-Ho Park et al.
Biochimica et biophysica acta, 1853(7), 1738-1748 (2015-04-23)
Vaccinia-related kinase 3 (VRK3) is known as a pseudokinase that is catalytically inactive due to changes in motifs that are essential for kinase activity. Although VRK3 has been regarded as a genuine pseudokinase from structural and biochemical studies, recent reports
Benjamin D Landry et al.
The EMBO journal, 33(9), 1044-1060 (2014-04-10)
To maintain genome stability, regulators of chromosome segregation must be expressed in coordination with mitotic events. Expression of these late cell cycle genes is regulated by cyclin-dependent kinase (Cdk1), which phosphorylates a network of conserved transcription factors (TFs). However, the
Nancy S Green et al.
Pediatric blood & cancer, 56(2), 177-181 (2010-09-11)
Fetal hemoglobin (HbF) levels are generally inversely proportional to severity of sickle cell disease (SCD) for given sickle phenotypes. Molecular regulation of HbF occurs through complex interactions cis and trans to the beta globin gene locus. Novel insights made through
Zhe Meng et al.
Urology, 82(6), 1452-1452 (2013-12-04)
To investigate the expression of 5-lipoxygenase (5-LOX) in metastatic prostate cancer and whether zileuton, the inhibitor of 5-LOX, plays a role in the metastasis of prostate cancer. An enzyme-linked immunosorbent assay was used to measure 5-hydroxyeicosatetraenoic acid (5-HETE) in patient
Stephan Kreher et al.
Annals of hematology, 93(12), 1953-1963 (2014-10-14)
Patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) like polycythemia vera and essential thrombocythemia are at increased risk of arterial and venous thrombosis. Strategies of prevention may consist of platelet aggregation inhibitors and/or cytoreductive agents depending on the underlying disease and
Management of patients with sickle cell disease.
Simeon Pollack
JAMA, 313(1), 90-91 (2015-01-07)
Flavia Rubia Pallis et al.
British journal of haematology, 164(2), 286-295 (2014-01-05)
Inflammation, leucocyte and red cell adhesion to the endothelium contribute to the pathogenesis of sickle cell anaemia. Neutrophils appear to be important for vaso-occlusion, however, eosinophils may also participate in this phenomenon. The role of eosinophils in the pathophysiology of
Hydroxyurea-induced leg ulceration in a patient with a homozygous MTHFR polymorphism misdiagnosed as pyoderma gangrenosum.
Sunita C Crittenden et al.
JAMA dermatology, 150(7), 780-781 (2014-03-07)
Sapna Oberoi et al.
Journal of pediatric hematology/oncology, 36(3), e140-e144 (2013-11-28)
Compound heterozygous HbSD-Punjab is an uncommon hemoglobinopathy encountered in Indians. Limited literature is available about its clinical course. The aim of this study was to describe the clinical and hematological profile of HbSD-Punjab patients from North India. HbSD-Punjab patients diagnosed
Olga Tsaponina et al.
Nucleic acids research, 41(22), 10371-10378 (2013-09-21)
The genome integrity checkpoint is a conserved signaling pathway that is regulated in yeast by the Mec1 (homologous to human ATR) and Rad53 (homologous to human Chk1) kinases. The pathway coordinates a multifaceted response that allows cells to cope with
Jana Peremartí et al.
Toxicological sciences : an official journal of the Society of Toxicology, 142(1), 93-104 (2014-08-06)
Chronic arsenic exposure is known to enhance the genotoxicity/carcinogenicity of other DNA-damaging agents by inhibiting DNA repair activities. Interference with nucleotide excision repair and base excision repair are well documented, but interactions with other DNA repair pathways are poorly explored
Dominga Iacobazzi et al.
Antioxidants & redox signaling, 21(11), 1591-1604 (2014-02-12)
Vascular wall-resident progenitor cells hold great promise for cardiovascular regenerative therapy. This study evaluates the impact of oxidative stress on the viability and functionality of adventitia-derived progenitor cells (APCs) from vein remnants of coronary artery bypass graft (CABG) surgery. We
Toru Nakayashiki et al.
Journal of bacteriology, 195(9), 2039-2049 (2013-03-05)
We have performed a screening of hydroxyurea (HU)-sensitive mutants using a single-gene-deletion mutant collection in Escherichia coli K-12. HU inhibits ribonucleotide reductase (RNR), an enzyme that catalyzes the formation of deoxyribonucleotides. Unexpectedly, seven of the mutants lacked genes that are
Esther Julián et al.
PloS one, 10(3), e0122049-e0122049 (2015-03-18)
The emergence of multidrug-resistant bacteria has encouraged vigorous efforts to develop antimicrobial agents with new mechanisms of action. Ribonucleotide reductase (RNR) is a key enzyme in DNA replication that acts by converting ribonucleotides into the corresponding deoxyribonucleotides, which are the
Ayalew Tefferi et al.
American journal of hematology, 90(2), 162-173 (2015-01-23)
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms, respectively characterized by erythrocytosis and thrombocytosis. Other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus, and risk of leukemic or fibrotic transformation. PV is defined by a JAK2
Erica B Esrick et al.
American journal of hematology, 90(7), 624-628 (2015-03-27)
Other than hydroxyurea, no pharmacologic agents are clinically available for fetal hemoglobin (HbF) induction in sickle cell disease (SCD). An optimal candidate would induce HbF without causing cell cycle inhibition and would act independently of hydroxyurea in order to yield
Raoul Tibes et al.
Expert opinion on emerging drugs, 18(3), 393-404 (2013-08-24)
Polycythemia vera (PV) patients suffer from disease-related constitutional symptoms, cardiovascular complications and risk of transformation into myelofibrosis and acute leukemia. Clinical and molecular aspects and current therapies will be described to provide clinical and molecular background to understand the natural
Gui-Zhen Wang et al.
Cancer science, 106(7), 902-908 (2015-04-22)
The Fanconi anemia (FA) pathway plays a key role in interstrand crosslink (ICL) repair and maintenance of the genomic stability, while inhibition of this pathway may sensitize cancer cells to DNA ICL agents and ionizing radiation (IR). The active FA
Dorota Rybaczek et al.
PloS one, 10(11), e0142307-e0142307 (2015-11-07)
We have demonstrated that the activation of apoptosis-like programmed cell death (AL-PCD) was a secondary result of caffeine (CF) induced premature chromosome condensation (PCC) in hydroxyurea-synchronized Vicia faba root meristem cells. Initiation of the apoptotic-like cell degradation pathway seemed to
Mehran Karimi
Hemoglobin, 33 Suppl 1, S177-S182 (2009-12-17)
Hydroxyurea (HU) is an antineoplastic agent that enhances fetal hemoglobin. The clinical significance induced by this compound is well known in sickle cell disease. This clinical significance could also be expected in beta-thalassemia patients. Although studies on beta-thalassemia major patients
M S Mahbub et al.
Mymensingh medical journal : MMJ, 22(1), 116-130 (2013-02-19)
A clinical trial study in the treatment of psoriasis was conducted in twenty three patients. The patients of psoriasis attending at the department of Dermatology and Venereology, BSMMU, Dhaka during the period of July 2009 to May 2010 were enrolled
Russell E Ware et al.
Hematology. American Society of Hematology. Education Program, 62-69 (2009-12-17)
Clinical experience with hydroxyurea for patients with sickle cell disease (SCD) has been accumulating for the past 25 years. The bulk of the current evidence suggests that hydroxyurea is well-tolerated, safe, and efficacious for most patients with SCD. Hydroxyurea has
Chung-Hui Yang et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 35(4), 1396-1410 (2015-01-30)
Drosophila melanogaster egg-laying site selection offers a genetic model to study a simple form of value-based decision. We have previously shown that Drosophila females consistently reject a sucrose-containing substrate and choose a plain (sucrose-free) substrate for egg laying in our
Bullet 'manicure': does lead prevent hydroxyurea-induced cutaneous toxicity?
Lorenzo Falchi et al.
Japanese journal of clinical oncology, 44(5), 512-512 (2014-05-02)
Alberto Alvarez-Larrán et al.
Annals of hematology, 93(12), 2037-2043 (2014-07-02)
Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited. Busulfan is effective as first-line therapy, but there is scarce information on this drug as second-line treatment. The efficacy of busulfan
Veronika Anyigoh Atemnkeng et al.
PloS one, 8(3), e58318-e58318 (2013-03-19)
Primaquine, an 8-aminoquinoline, is the only drug which cures the dormant hypnozoites of persistent liver stages from P. vivax. Increasing resistance needs the discovery of alternative pathways as drug targets to develop novel drug entities. Deoxyhypusine hydroxylase (DOHH) completes hypusine
I A Lagunju et al.
The Nigerian postgraduate medical journal, 20(3), 181-187 (2013-11-30)
To compare the outcome after a first clinical stroke, following treatment with and without hydroxyurea (HU). A retrospective review of a cohort of Nigerian children with SCD, who had suffered a first stroke, was carried out. Outcomes in the group
Linyu Deng et al.
The Cochrane database of systematic reviews, 1(1), CD005196-CD005196 (2013-02-27)
This is an update of the original review that was published in The Cochrane Database of Systematic Reviews, 2009, Issue 2. Gestational trophoblastic neoplasia (GTN) are malignant disorders of the placenta that include invasive hydatidiform mole, choriocarcinoma, placental-site trophoblastic tumour
Mehdi Banan
Annals of hematology, 92(3), 289-299 (2013-01-16)
Hydroxyurea (HU) is a drug that induces fetal hemoglobin production. As a result, HU is widely used to treat β-thalassemia (β-thal) patients. However, the response of these patients to HU varies. Some β-thal patients respond favorably to treatment while others
Page 1 of 7